Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Prostate cancer screening practices in a large, integrated health system: 2007-2014.

Misra-Hebert AD, Hu B, Klein EA, Stephenson A, Taksler GB, Kattan MW, Rothberg MB.

BJU Int. 2017 Aug;120(2):257-264. doi: 10.1111/bju.13793. Epub 2017 Feb 26.

PMID:
28139034
2.

The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.

Fleshner K, Carlsson SV, Roobol MJ.

Nat Rev Urol. 2017 Jan;14(1):26-37. doi: 10.1038/nrurol.2016.251. Epub 2016 Dec 20. Review.

3.

Prostate Cancer Screening: A Brief Tool to Incorporate Patient Preferences in a Clinical Encounter.

Misra-Hebert AD, Kattan MW.

Front Oncol. 2016 Nov 4;6:235. eCollection 2016. No abstract available.

4.

Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.

Li J, Dai L, Lei N, Xing M, Li P, Luo C, Casiano CA, Zhang JY.

Oncotarget. 2016 Jul 12;7(28):43546-43556. doi: 10.18632/oncotarget.9869.

5.
6.

Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens.

Dai L, Li J, Ortega R, Qian W, Casiano CA, Zhang JY.

J Immunol Res. 2014;2014:827827. doi: 10.1155/2014/827827. Epub 2014 Apr 17.

7.

Mammography use among women ages 40-49 after the 2009 U.S. Preventive Services Task Force recommendation.

Block LD, Jarlenski MP, Wu AW, Bennett WL.

J Gen Intern Med. 2013 Nov;28(11):1447-53. doi: 10.1007/s11606-013-2482-5. Epub 2013 May 15.

8.

Prostate cancer screening in men ages 75 and older fell by 8 percentage points after Task Force recommendation.

Howard DH, Tangka FK, Guy GP, Ekwueme DU, Lipscomb J.

Health Aff (Millwood). 2013 Mar;32(3):596-602. doi: 10.1377/hlthaff.2012.0555.

9.

Prostate-specific antigen testing in men aged 40-64 years: impact of publication of clinical trials.

Goodwin JS, Tan A, Jaramillo E, Kuo YF.

J Natl Cancer Inst. 2013 May 15;105(10):743-5. doi: 10.1093/jnci/djt039. Epub 2013 Mar 4.

10.

A preliminary exploration of the feasibility of offering men information about potential prostate cancer treatment options before they know their biopsy results.

Zeliadt SB, Hannon PA, Trivedi RB, Bonner LM, Vu TT, Simons C, Kimmie CA, Hu EY, Zipperer C, Lin DW.

BMC Med Inform Decis Mak. 2013 Feb 6;13:19. doi: 10.1186/1472-6947-13-19.

11.

Primary care physicians' use of an informed decision-making process for prostate cancer screening.

Volk RJ, Linder SK, Kallen MA, Galliher JM, Spano MS, Mullen PD, Spann SJ.

Ann Fam Med. 2013 Jan-Feb;11(1):67-74. doi: 10.1370/afm.1445.

12.

LHRH Agonists for the Treatment of Prostate Cancer: 2012.

Lepor H, Shore ND.

Rev Urol. 2012;14(1-2):1-12.

13.

Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries.

Ross JS, Wang R, Long JB, Gross CP, Ma X.

Arch Intern Med. 2012 Nov 12;172(20):1601-3. doi: 10.1001/archinternmed.2012.3726. No abstract available.

14.

The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States.

Howrey BT, Kuo YF, Lin YL, Goodwin JS.

J Gerontol A Biol Sci Med Sci. 2013 Jan;68(1):56-61. doi: 10.1093/gerona/gls135. Epub 2012 May 4.

15.

Improved blood tests for cancer screening: general or specific?

Cree IA.

BMC Cancer. 2011 Nov 30;11:499. doi: 10.1186/1471-2407-11-499.

Supplemental Content

Support Center